Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2013-09-11 Investor Presentation
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Investor update 2 pages 190.5KB
Investor Presentation Classification · 95% confidence The document is a newsletter from Invion Limited, dated for the second half of 2013, containing a letter from the CEO, updates on clinical trials, investor relations activities, upcoming presentations, company overview, and media mentions. It is a communication aimed at investors providing business updates and strategic outlook rather than a formal financial report or regulatory filing. There are no financial statements, audit information, or detailed financial data present. The content is consistent with an Investor Presentation or company newsletter rather than an Annual Report, Interim Report, or Earnings Release. Given the detailed business and clinical progress updates and investor engagement information, the best fitting category is Investor Presentation (IP). The document length (6794 characters) supports it being a substantive update rather than a brief announcement or certification. Therefore, the classification is IP with high confidence.
2013-09-11 English
Invion presents at Rodman & Renshaw Global Conference 26 pages 1.4MB
Investor Presentation Classification · 95% confidence The document is a media announcement from Invion Limited about their participation in the 15th Annual Rodman & Renshaw Global Investment Conference. It includes a detailed corporate presentation with information about the company's management, drug pipeline, clinical trials, market opportunities, and regulatory status. The content is structured as a presentation aimed at investors, focusing on business overview, strategy, and clinical development progress. There are no financial statements or detailed financial performance data typical of annual or interim reports. The document is not an earnings release, audit report, or regulatory filing. It is clearly a presentation for investors, consistent with the definition of an Investor Presentation (IP). The length (15,000 characters) and detailed content support this classification with high confidence.
2013-09-08 English
App 4E / Full Year Statutory Accounts 80 pages 1.3MB
Regulatory Filings
2013-08-22 English
Change in substantial holding 3 pages 277.1KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001. It details changes in voting power and relevant interests of a substantial shareholder, Invion Limited, including dates and share counts. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2013-08-14 English
Change of Director's Interest Notice 3 pages 217.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities held by a director, including number of shares before and after the change, nature of the change, and dates. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It is not an annual report, earnings release, or any other financial report. The document length is 4096 characters, which is typical for such notices. Therefore, the correct classification is Director's Dealing (DIRS).
2013-08-14 English
Change of Director's Interest Notice 2 pages 219.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed information about changes in a director's relevant interests in securities, including number of shares held before and after the change, nature of the change, and dates. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure related to insider trading or director shareholdings. The content is specific to a director's personal share transactions and does not include financial performance data, management discussion, or other report types. Therefore, it fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3688 characters, which is typical for such notices and not a report publication announcement. Hence, the correct classification is DIRS with high confidence.
2013-08-14 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.